Antiviral effect of palmatine against infectious bronchitis virus through regulation of NF-κB/IRF7/JAK-STAT signalling pathway and apoptosis

British Poultry Science, Journal Year: 2024, Volume and Issue: 65(2), P. 119 - 128

Published: Jan. 3, 2024

1. Infectious bronchitis virus (IBV), a gamma-coronavirus, can infect chickens of all ages and leads to an acute contact respiratory infection. This study evaluated the anti-viral activity palmatine, natural non-flavonoid alkaloid, against IBV in chicken embryo kidney (CEK) cells.

Language: Английский

---

Effect of interferon therapy on quality of life in patients with chronic hepatitis B

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Jan. 30, 2024

Abstract Interferon therapy is the most effective treatment for achieving clinical cure in chronic hepatitis B (CHB) patients. However, outcomes of interferon are uncertain, multiple side effects can occur during treatment, and expensive. Although these characteristics may affect patients’ quality life, research examining this topic limited. We used a cross-sectional design to examine 100 CHB patients receiving interferon, nucleoside/nucleotide analogues, 87 non-antiviral treatment. Characteristic information, Hepatitis Quality Life Instrument, Connor Davidson Resilience Scale, Work Productivity Activity Impairment Questionnaire were collect information. found that life group was higher than analogue groups ( p < 0.05). The factors influencing resilience, presenteeism, hair loss, antiviral has some potential effects, results suggested it did not negatively life. Overall, have major impact on daily lives work.

Language: Английский

---

miR-3188 inhibits hepatitis B virus transcription by targeting Bcl-2

Archives of Virology, Journal Year: 2024, Volume and Issue: 169(5)

Published: April 2, 2024

Language: Английский

---

Interim analysis of the PARADISE study: Benefits of add-on peginterferon-α in NA-treated patients with CHB

Antiviral Research, Journal Year: 2024, Volume and Issue: 226, P. 105892 - 105892

Published: April 23, 2024

This study aimed to investigate whether peginterferon-α (IFN) add-on nucleos(t)ide analogs(NAs) can further reduce hepatocellular carcinoma(HCC) risk compared with NAs monotherapy in NA-treated patients chronic hepatitis B(CHB). In this multi-center randomized controlled trial "PARADISE study" (NCT05671315), CHB intermediate high of HCC after more than 24-week pretreatment were recruited, two groups at a ratio 1:2 and followed up for 240 weeks. group maintained monotherapy, while IFN+NAs received IFN therapy 48 weeks, then switched monotherapy. Totally, 196 included interim analysis (NAs 68, 128). The 96-week cumulative incidence was lower (0% vs. 4.5%, p<0.05). Compared group, had significantly higher rates HBsAg loss week 96 (22.7% 0%; 16.7% 0%, both A new scoring system established predict decline >2log10 IU/ml, <10 IU/ml or the end 48-week treatment. area under ROC curve 0.914, 0.922 0.905 original cohort (n=128) 0.896, 0.896 0.864 external validation (n=162) aforementioned three outcomes, respectively. may suggest dual benefits reducing development facilitating among HCC. helps make most treatment cost-effectiveness healthcare.

Language: Английский

---

Recent Advances in Antivirals for Japanese Encephalitis Virus

Viruses, Journal Year: 2023, Volume and Issue: 15(5), P. 1033 - 1033

Published: April 23, 2023

Culex mosquitoes are the primary vectors of Japanese encephalitis virus (JEV). Since its discovery in 1935, (JE), caused by JEV, has posed a significant threat to human health. Despite widespread implementation several JEV vaccines, transmission chain natural ecosystem not changed, and vector cannot be eradicated. Therefore, is still focus attention for flaviviruses. At present, there no clinically specific drug JE treatment. infection complex interaction between host cell, which design development. An overview antivirals that target elements factors presented this review. In addition, drugs balance antiviral effects protection regulating innate immunity, inflammation, apoptosis, or necrosis reviewed treat effectively.

Language: Английский

---

Mechanism of action and treatment of type I interferon in hepatocellular carcinoma

Clinical & Translational Oncology, Journal Year: 2023, Volume and Issue: 26(2), P. 326 - 337

Published: July 4, 2023

Language: Английский

---

Chicken Interferon-Alpha and -Lambda Exhibit Antiviral Effects against Fowl Adenovirus Serotype 4 in Leghorn Male Hepatocellular Cells

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(3), P. 1681 - 1681

Published: Jan. 30, 2024

Hydropericardium hepatitis syndrome (HHS) is primarily caused by fowl adenovirus serotype 4 (FAdV-4), causing high mortality in chickens. Although vaccination strategies against FAdV-4 have been adopted, HHS still occurs sporadically. Furthermore, no effective drugs are available for controlling infection. However, type I and III interferon (IFN) crucial therapeutic agents viral The following experiments were conducted to investigate the inhibitory effect of chicken IFN FadV-4. We expressed recombinant IFN-α (ChIFN-α) IFN-λ (ChIFN-λ) Escherichia coli systemically investigated their antiviral activity infection Leghorn male hepatocellular (LMH) cells. ChIFN-α ChIFN-λ dose dependently inhibited replication LMH Compared with ChIFN-λ, more significantly genome transcription but less suppressed release. ChIFN-α- ChIFN-λ-induced IFN-stimulated gene (ISG) expression, such as PKR, ZAP, IRF7, MX1, Viperin, IFIT5, OASL, IFI6, cells; however, induced a stronger expression level than ChIFN-λ. Thus, our data revealed that might trigger different ISG levels, inhibiting via steps lifecycle, which furthers potential applications

Language: Английский

---

Tripartite motif-containing protein 21 is involved in IFN-γ-induced suppression of hepatitis B virus by regulating hepatocyte nuclear factors

Journal of Virology, Journal Year: 2024, Volume and Issue: 98(6)

Published: May 23, 2024

The antiviral role of the tripartite motif-containing (TRIM) protein family , a member E3-ubiquitin ligase family, has recently been actively studied. Hepatitis B virus (HBV) infection is major contributor to liver diseases; however, host factors regulated by cytokine-inducible TRIM21 suppress HBV remain unclear. In this study, we showed efficacy against in hepatoma cell lines, primary human hepatocytes isolated from patient tissues, and mouse model. Using knock-out cells, confirmed that effects interferon-gamma, which replication, are diminished when deficient. Northern blot analysis reduction RNA levels TRIM21. Luciferase reporter assay, also discovered decreases activity enhancers, play crucial covalently closed circular DNA transcription. participation RING domain PRY-SPRY anti-HBV effect was demonstrated through experiments using deletion mutants. We identified novel interaction between hepatocyte nuclear factor 4α (HNF4α) co-immunoprecipitation assay. More specifically, ubiquitination assay revealed promotes ubiquitin-mediated proteasomal degradation HNF4α. HNF1α transcription down-regulated as result HNF4α, an activator for promoter. Therefore, key enhancer activators, HNF4α HNF1α, resulted decline transcription, ultimately leading inhibition replication.IMPORTANCEDespite extensive research efforts, definitive cure chronic hepatitis remains elusive, emphasizing persistent importance viral substantial public health concern. Although risks associated with well known, capable suppressing largely uncharacterized. This study elucidates 21 (TRIM21) suppresses consequently inhibits replication downregulating factors, enhancers. Our findings demonstrate mechanism interferon-gamma-induced activity. These may contribute new strategies block HBV.

Language: Английский

---

Unraveling IFI44L’s biofunction in human disease

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Dec. 16, 2024

Interferon-induced protein 44-like (

Language: Английский

---

Host and HBV Interactions and Their Potential Impact on Clinical Outcome

Published: Aug. 15, 2023

Hepatitis B Virus (HBV) is a challenge for global health services, affecting millions and leading hundreds to end-stage liver disease each year. This comprehensive review explores the interactions between HBV host, examining their impact on clinical outcomes. infection encompasses spectrum of severity, ranging from acute hepatitis chronic B, which can potentially progress cirrhosis hepatocellular carcinoma (HCC). Occult (OBI), characterized by low DNA levels in surface antigen-negative individuals, reactivate cause B. The identification diverse genotypes reveals distinct geographical distributions associations with Moreover, single nucleotide polymorphisms (SNPs) within host genome have been linked several outcomes, including cirrhosis, HCC, OBI, reactivation, spontaneous clearance. immune response plays key role controlling eliminating infected cells neutralizing bloodstream. Furthermore, modulate metabolic pathways involved glucose lipid metabolism bile acid absorption, further influencing progression. outcomes correlate three viral adaptation. In conclusion, could result complex HBV. These vary among populations are influenced genotypes, genetics, environmental factors, lifestyle. Understanding degrees adaptation essential developing region-specific control prevention measures.

Language: Английский

---